½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 3 March 2023 ¨C 20:00 (CET) ¨C Regulated information

Acquisition of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀֳǠSA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2023.

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 500 000 ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 28 April 2023, effective as from 27 February 2023, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2023, ½ðºÌÓéÀÖ³Ç repurchased 116 660 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 27 February 2023 up to and including 2 March 2023, as follows:

This press release is available on ½ðºÌÓéÀֳǠSA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç:

Investor Relations
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com      

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in 36 countries, the company generated revenue of € 5.5 billion in 2022. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news